NK-1 receptor antagonists: A new paradigm in pharmacological therapy

Current Medicinal Chemistry

Volumn 18, Issue 12, 2011, Pages 1820-1831

  Munoz M ^a   Covenas R ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Analgesic; Antialcohol addiction; Antidepressant; Antiinflammatory; Antitumour; Antivirus proliferation; Anxyolitic; Substance P

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; APREPITANT; DAPITANT; DEXAMETHASONE; EZLOPITANT; FOSAPREPITANT; L 709210; L 737488; LANEPITANT; LY 686017; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NOLPITANTIUM; OVERPITANT; PLACEBO; SEROTONIN 3 ANTAGONIST; SSR 240600; SUBSTANCE P; UNCLASSIFIED DRUG; VESTIPITANT; VINBLASTINE; VOFOPITANT;

ACUTE HEPATITIS; ADDICTION; ALCOHOLISM; ANALGESIC ACTIVITY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY; ANXIETY DISORDER; APOPTOSIS; ARTICLE; ASTHMA; CELL MIGRATION; CELL PROLIFERATION; CHOLESTASIS; CHRONIC BRONCHITIS; CHRONIC HEPATITIS; DEGENERATIVE DISEASE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; EMOTIONALITY; ENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LIVER TOXICITY; MEASLES; MEASLES VIRUS; METASTASIS; MIGRAINE; MYOCARDITIS; NAUSEA; NEOPLASM; NERVE DEGENERATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROPROTECTION; NONHUMAN; PAIN; PROTEIN FUNCTION; PRURITUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHEUMATOID ARTHRITIS; SARCOIDOSIS; STRESS; SUBACUTE SCLEROSING PANENCEPHALITIS; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTORS, NEUROKININ-1;

EID: 79955680163     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795496746     Document Type: Article

References (136)

1. Kuhn, T.S. The Structure of Scientific Revolution, University of Chicago Press: Chicago, 1962.
2. Taleb, N.N. The Black Swan: The Impact of the Highly Improbable, Random House: New York, 2007.
3. Cuello, A.C.; Kanazawa, I. The distribution of substance P immunoreactive fibres in the rat central nervous system. J. Comp. Neurol., 1978, 178, 129-156.
4. Hökfelt, T.; Pernow, B.; Nilsson, G.; Wetterberg, L.; Goldstein, M.; Jeffcoate, S.L. Dense plexus of substance P-immunoreactive nerve terminals in eminentia medialis of the primate hypothalamus. Proc. Natl. Acad. Sci. USA, 1978, 74, 1013-1015. (Pubitemid 8298503)
5. Mai, J.K.; Stephens, P.H.; Hopf, A.; Cuello, A.C. Substance P in the human brain. Neuroscience, 1986, 17, 709-739. (Pubitemid 16131267)
6. Burgos, C.; Aguirre, J.A.; Alonso, J.R.; Coveñas, R. Immunocytochemical study of substance P-like fibres and cell bodies in the cat diencephalon. J. Hirnforsch., 1988, 29, 651-657. (Pubitemid 19046442)
7. Wolf, S.S.; Moody, T.W.; Quirion, R.; O'Donohue, T.L. Biochemical characterization and autoradiographic localization of central SP receptor using [125I] physalaemin. Brain Res., 1985, 332, 299-307. (Pubitemid 15108000)
8. Dam, T.V.; Quirion, R. Pharmacological characterization and autoradiographic characterization of substance P receptors in guinea-pig brain. Peptides, 1986, 7, 855-864. (Pubitemid 17182354)
9. Danks, J.A.; Rothman, R.B.; Cascieri, M.A.; Chicchi, G.G.; Liang, T.; Herkenham, M. A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain. Brain Res., 1986, 385, 273-281. (Pubitemid 16006841)
10. Saffroy, M.; Beaujouan, J.C.; Torrens, Y.; Besseyre, J.; Bergstrom, L.; Glowinski, J. Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain. Peptides, 1988, 9, 227-241. (Pubitemid 19260226)
11. Maeno, H.; Kiyama, H.; Tohyama, M. Distribution of the substance P (NK1) receptor in the central nervous system. Mol. Brain Res., 1993, 18, 43-58.
12. Nakaya, Y.; Kaneko, T.; Shigemoto, R.; Nakanishi, S.; Mizuno, N. Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J. Comp. Neurol., 1994, 347, 249-274. (Pubitemid 24273427)
13. Whitty, C.J.; Walker, P.D.; Goebel, D.J.; Poosch, M.S.; Bannon, M.J. Quantitation, cellular localization and regulation of neurokinin receptor gene expression whithin the rat substantia nigra. Neuroscience, 1995, 64, 419-425.
14. Almeida, T.; Rojo, J.; Nieto, P.M. Tachykinins and tachykinin receptor: structure and activity relationships. Curr. Med. Chem., 2004, 11, 763-771.
15. Unger, T.; Rascher, W.; Schuster, C.; Pavlovitch, R.; Schömig, A.; Dietz, R.; Ganten, D. Central blood pressure effects of substance P and angiotensin II: role of the sympathetic nervous system and vasopressin. Eur. J. Pharmacol., 1981, 71, 33-42. (Pubitemid 11112563)
16. Rupniak, N.M.; Carlson, E.; Boyce, S.; Webb, J.K.; Hill, R.G. Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L- 733,060 in gerbils. Pain, 1996, 67, 189-195. (Pubitemid 26319652)
17. Quartara, L.; Maggi, C.A. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides, 1998, 32, 1-49. (Pubitemid 28167857)
18. Kramer, M.S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J.J.; Reines, S.A.; Liu, G.; Snavely, D.; Wyatt-knowles, E.; Halle, J.J.; Mills, S.G.; MacCoss, M.; Swain, C.J.; Harrison, T.; Hill, R.G.; Hefti, F.; Scolnick, E.M.; Cascieri, M.A.; Chicchi, G.G.; Sadowski, S.; Williams, A.R.; Hewson, L.; Smith, D.; Carlsson, E.J.; Hargreaves, R.J.; Rupniak, N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 1998, 281, 1640-1645. (Pubitemid 28435572)
19. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J.; Narváez, J.A.; Tramu, G. Simultaneous depletion of neurokinin A, substance P and calcitonin generelated peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain, 2000, 84, 389-395. (Pubitemid 30074242)
20. Harrison, S.; Geppetti, P. Substance P. Int. J. Biochem. Cell Biol., 2001, 33, 555-576.
21. Bang, R., Sass, G., Kiemer, A.K., Vollmar, A.M., Neuhuber, W.L., Tiegs, G. Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J. Pharmacol. Exp. Ther., 2003, 305, 31-39. (Pubitemid 36373833)
22. Schratzberger, P.; Reinisch, N.; Prodinger, W.M.; Kahler, C.M.; Sitte, B.A.; Bellmann, R.; Fischer-Colbrie, R.; Winkler, H.; Wiedermann, C.J. Differential chemotactic activities of sensory neuropeptides for human peripheral blood mononuclear cells. J. Immunol., 1997, 158, 3895-3901. (Pubitemid 127488749)
23. Ruff, M.R.; Wahl, S.M.; Pert, C.B. Substance P receptor-mediated chemotaxis of human monocytes Peptides, 1985, 6, 107-111. (Pubitemid 16211115)
24. Dunzendorfer, S.; Meierhofer, C.; Wiedermann, C.J. Signaling in neuropeptide- induced migration of human eosinophils J. Leukocyte Biol., 1998, 64, 828-834. (Pubitemid 28555398)
25. Feistritzer, C.; Clausen, J.; Sturn, D.H.; Djanani, A.; Gunsilius, E.; Wiedermann, C.J.; Kahler, C.M. Natural killer cell functions mediated by the neuropeptide substance P. Regul. Pept., 2003, 116, 119-126. (Pubitemid 37352922)
26. Meshki, J.; Douglas, S.D.; Lai, J.P.; Schwartz, L.; Kilpatrick, L.E.; Tuluc, F. Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J. Biol. Chem., 2009, 284, 9280-9289.
27. Fackler, O.T.; Grosse, R. Cell motility through plasma membrane blebbing. J. Cell Biol., 2008, 181, 879-884. (Pubitemid 351846821)
28. Janelsins, B.M.; Mathers, A.R.; Tkacheva, O.A.; Erdos, G.; Shufesky, W.J.; Morelli, A.E.; Larregina, A.T. Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. Blood, 2009, 113, 3017-3026.
29. Graham, G.J.; Stevens, J.M.; Page, N.M.; Grant, A.D.; Brain, S.D.; Lowry, P.J.; Gibbins, J.M. Tachykinins regulate the function of platelets. Blood, 2004, 104, 1058-1065. (Pubitemid 39038026)
30. Cho, K.J.; Trzaska, K.A., Greco, S.J.; McArdle, J.; Wang, F.S.; Ye, J.H.; Rameshwar, P. Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells, 2005, 23, 383-391. (Pubitemid 40404457)
31. Kawada, H.; Takizawa, S.; Takanashi, T.; Morita, Y.; Fujita, J.; Fukuda, K.; Takagi, S.; Okano, H.; Ando, K.; Hotta, T. Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation, 2006, 113, 701-710.
32. Park, S.W.; Yan, Y.P.; Satriotomo, I.; Vemuganti, R.; Dempsey, R.J. Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J. Neurosurg., 2007, 107, 593-599. (Pubitemid 47451044)
33. Snider, R.M.; Constantine, J.W.; Lowwe, I.J. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science, 1991, 251, 435-437. (Pubitemid 21916907)
34. Quartara, L.; Maggi, C.A. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides, 1997, 31, 537-563. (Pubitemid 28037471)
35. Muñoz, M.; Pérez, A.; Rosso, M.; Zamarriego, C.; Rosso, R. Antitumoural action of NK1 receptor antagonist L-733,060 on human melanoma cell lines. Melanoma Res., 2004, 14, 183-188. (Pubitemid 38879579)
36. Muñoz, M.; Rosso, M.; Pérez, A.; Coveñas, R.; Rosso, R.; Zamarriego, C.; Piruat, J.I. The NK1 receptor is involved in the antitumoural action of L- 733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides, 2005, 39, 427-432. (Pubitemid 41073623)
37. Muñoz, M.; Rosso, M.; Pérez, A.; Coveñas, R.; Rosso, R.; Zamarriego, C.; Soult, J.A.; Montero, I. Antitumoural action of the neurokinin-1- receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest. Ophthalmol. Vis. Sci., 2005, 46, 2567-2570. (Pubitemid 43119507)
38. Muñoz, M.; Rosso, M.; Coveñas, R. The NK-1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett. Drug Des. Discovery, 2006, 3, 323-329. (Pubitemid 43988115)
39. Rosso, M.; Robles-Frias, M.J.; Coveñas, R.; Salinas-Martín, M.V.; Muñoz, M. The NK-1 receptor is involved in the antitumor action of L-733,060 and in the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol., 2008, 29, 245-254.
40. MacLeod, A.M.; Merchant, K.J.; Brookfield, F.; Kelleher, F.; Stevenson, G.; Owens, A.P.; Swain, C.J.; Cascieri, M.A.; Sadowski, S.; Ber, E.; Strader, C.D.; Fong, T.M. Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. J. Med. Chem., 1994, 37, 1269-1274. (Pubitemid 24179468)
41. Cahill, C.M.; Coderre, T.J. Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain, 2002, 95, 277-285. (Pubitemid 34142651)
42. Muñoz, M.; Rosso, M.; Coveñas, R.; Montero, I.; González-Moles, M.A.; Robles, M.J. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest. Ophthalmol. Vis. Sci., 2007, 48, 2775-2781. (Pubitemid 351261233)
43. Muñoz, M.; Rosso, M.; Coveñas, R. In: Focus on Neuroblastoma Research, Fernandes, Ed.; Nova Science Publishers: New York, 2007; pp. 31-56.
44. Muñoz, M.; Rosso, M.; Aguilar, F.J.; González-Moles, M.A.; Redondo, M.; Esteban, F. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Investig. New Drugs, 2008, 26, 111-118.
45. Muñoz, M.; Rosso, M.; Robles-Frías, M.J.; Salinas-Martín, M.V.; Rosso, R.; González, A.; Coveñas, R. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab. Invest., 2010, 90, 1259-1269.
46. Hökfelt, T.; Pernow, B.; Wahren, J. Substance P: a pioneer amongst neuropeptides. J. Intern. Med., 2001, 249, 27-40. (Pubitemid 32147090)
47. Hesketh, P.J.; Gralla, R.J.; Webb, R.T.; Ueno, W.; DelPrete, S.; Bachinsky, M.E.; Dirlam, N.L.; Stack, C.B.; Silberman, S.L. Randomized Phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatininduced emesis. J. Clin. Oncol., 1999, 17, 338-343. (Pubitemid 29022412)
48. Rudd, J.A.; Jordan, C.C.; Naylor, R.J. The action of the NK1 tachykinin receptor antagonist CP-99,994 in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br. J. Pharmacol., 1996, 119, 931-936. (Pubitemid 26366488)
49. Elliott, P.J. Place aversion induced by the substance P analogue, dimetil-C7, is not state dependent: implication of substance P in aversion. Exp. Brain Res., 1988, 73, 354-356.
50. Ebner, K.; Rupniak, N.M.; Saria, A.; Singewald, N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. USA, 2004, 10, 4280-4285. (Pubitemid 38405920)
51. Ebner, K.; Singewald, G.M.; Whittle, N.; Ferraguti, F.; Singewald, N. Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission. Neuropsychopharmacology, 2008, 33, 1929-1941. (Pubitemid 351832607)
52. Ebner, K.; Muigg, P.; Singewald, G.; Singewald, N. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann. NY Acad. Sci., 2008, 1144, 61-73.
53. Ebner, K.; Singewald, N. Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch. Pharmacol., 2007, 376, 73-78.
54. Teixeira, R.M.; Santos, A.R.; Ribeiro, S.J.; Calixto, J.B.; Rae, G.A.; De Lima, T.C. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol., 1996, 311, 7-14. (Pubitemid 26298493)
55. Rupniak, N.M.; Carlson, E.C.; Harrison, T.; Oates, B.; Seward, E.; Owen, S.; de Felipe, C.; Hunt, S.; Wheeldon, A. Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology, 2000, 39, 1413-1421. (Pubitemid 30249203)
56. Rupniak, N.M.; Calrson, E.J.; Webb, J.K.; Harrison, T.; Porsolt, R.D.; Roux, S.; de Felipe, C.; Hunt, S.P.; Oates, B.; Wheeldon, A. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav. Pharmacol., 2001, 12, 497-508. (Pubitemid 33152274)
57. Varty, G.B.; Morgan, C.A.; Cohen-Williams, M.E.; Coffin, V.L.; Carey, G.J. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation. Neuropsychopharmacology, 2002, 27, 357-370. (Pubitemid 35253784)
58. Wallace-Boone, T.L.; Newton, A.E.; Wright, R.N.; Lodge, N.J.; McElroy, J.F. Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists. Neuropsychopharmacology, 2008, 33, 1919-1928. (Pubitemid 351832600)
59. Humpel, C.; Knaus, G.A.; Auer, B.; Knaus, H.G.; Haring, C.; Theodorson, E.; Saria, A. Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato- nigral system. Synapse, 1990, 6, 1-9.
60. Shibata, K.; Haverstick, D.M.; Bannon, M.J. Tachykinin gene expression in rat limbic nuclei: modulation by dopamine antagonists. J. Pharmacol. Exp. Ther., 1990, 255, 388-392. (Pubitemid 20361530)
61. Shirayama, Y.; Mitsushio, H.; Takashima, M.; Ichinawa, H.; Takahashi, K. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res., 1996, 739, 70-78. (Pubitemid 26387364)
62. Varty, G.B.; Cohen-Williams, M.E.; Hunter, J.C. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav. Pharmacol., 2003, 14, 87-95. (Pubitemid 36279029)
63. Keller, M.; Montgomery, S.; Ball, W.; Morrison, M.; Snavely, D.; Liu, G.; Hargreaves, R.; Hietala, J.; Lines, C.; Beebe, K.; Reines, S. Lack of efficacy of the substance P (neurokinin-1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry., 2006, 59, 216-223. (Pubitemid 43208967)
64. Holzer, P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience, 1988, 24, 739-768.
65. Jang, J.H.; Nam, T.S.; Paik, K.S.; Leem, J.W. Involvement of peripherally released substance P and calcitonin gene-related peptide in mediating mechanical hyperalgesia in a traumatic neuropathy model of the rat. Neurosci. Lett., 2004, 360, 129-132. (Pubitemid 38479750)
66. Rittner, H.L.; Lux, C.; Labuz, D.; Mousa, S.A.; Achäfer, M.; Stein, C.; Brack, A. Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception. Anesthesiology, 2007, 107, 1009-1017. (Pubitemid 350175684)
67. Cao, Y.Q.; Mantyh, P.W.; Carlson, E.J.; Gillespie, A.M.; Epstein, C.J.; Basbaum, A.I. Primary afferent tachykinins are required to experience moderate to intense pain. Nature, 1998, 392, 390-394. (Pubitemid 28168735)
68. Shibata, H.; Mio, M.; Tasaka, K. Analysis of the mechanism of histamine release induced by substance P. Biochem. Biophys. Acta, 1985, 846, 1-7. (Pubitemid 15012789)
69. Lembeck, F.; Donnerer, J.; Tsuchiya, M.; Nagahisa, A. The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation. Br. J. Pharmacol., 1992, 105, 527-530.
70. Hughes, S.R.; Williams, T.J.; Brain, S.D. Evidence that endogenous nitric oxide modulates edema formation induced by substance P. Eur. J. Pharmacol., 1990, 191, 481-484.
71. Lai, J.P.; Douglas, S.D.; Rappaport, E.; Wu, J.M.; Ho, W.Z. Identification of a delta isoform of preprotachykinin mRNA in human mononuclear phagocytes and lymphocytes. J. Neuroimmunol., 1998, 91, 121-128. (Pubitemid 28545252)
72. Lambrecht, B.N.; Germonpre, P.R.; Everaert, E.G.; Carro-Muino, I.; De Veerman, M.; de Felipe, C.; Hunt, S.P.; Thielemans, K.; Joos, G.F.; Pauwels, R.A. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur. J. Immunol., 1999, 29, 3815-3825.
73. Scicchinato, R.; Biennenstock, J.; Stanisz, A.M. In vivo immunomodulation by the neuropeptide substance P. Immunology, 1988, 63, 733-735.
74. Nio, D.A.; Moylan, R.N.; Roche, J.K. Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements. J. Immunol., 1993, 150, 5281-5288. (Pubitemid 23180641)
75. O'Connor, T.M.; O'Connell, J.; O'Brien, D.I.; Goode, T.; Verdin, C.P.; Sanan, F. The role of substance P in inflammatory disease. J. Cell. Physiol., 2004, 201, 167-180. (Pubitemid 39305095)
76. Blau, J.N. Migraine: theories of pathogenesis. Lancet, 1992, 339, 1202-1207.
77. Moskowitz, MA. The visceral organ grain: implications for the pathophysiology of vascular head pain. Neurology, 1991, 41, 182-186.
78. Samsam, M.; Coveñas, R.; Csillik, B.; Ahangari, R.; Yajeya, J.; Riquelme, R.; Narváez, J.A.; Tramu, G. Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion: a possible neurophysiological and neuroanatomical link to generalized head pain. J. Chem. Neuroanat., 2001, 21, 161-169. (Pubitemid 32324239)
79. Bolay, H.; Reuter, U.; Dunn, A.K.; Huang, Z.; Boas, D.A.; Moskowitz, M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med., 2002, 8, 136-142. (Pubitemid 34155124)
80. Murtra, P.; Sheasby, A.M.; Hunt, S.P.; de Felipe, C. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature, 2000, 405, 180-3. (Pubitemid 30313535)
81. Angulo, J.A.; McEwen, B.S. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. Brain Res.Brain Res.Rev., 1994, 19, 1-28. (Pubitemid 24024082)
82. Reid, M.S.; Herrera-Marschitz, M.; Kehr, J.; Ungerstedt, U. Striatal dopamine and glutamate release: effects of intranigral injections of substance P. Acta Physiol. Scand., 1990, 140, 527-537.
83. Reid, M.S.; Herrera-Marschitz, M.; Hökfelt, T.; Ohlin, M.; Valentino, K.L.; Ungerstedt, U. Effects of intranigral substance P and neurokinin A on striatal dopamine release - I. Interactions with substance P antagonists. Neuroscience, 1990, 36, 643-658. (Pubitemid 20282179)
84. Yu, J.; Cadet, J.L.; Angulo, J.A. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J. Neurochem., 2002, 83, 613-622. (Pubitemid 35231815)
85. Liu, H.; Cao, Y.; Basbaum, A.I.; Mazarati, A.M.; Sankar, R.; Wasterlain, C.G. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc. Natl. Acad. Sci. USA, 1999, 96, 12096-12101. (Pubitemid 29502864)
86. Zachrisson, O.; Lindefor, N.; Brené, S. A tachykinin NK1 receptor antagonist, CP-122,721, attenuates kainic acid-induced seizure activity. Brain Res. Mol. Brain Res., 1998, 60, 291-295. (Pubitemid 28466593)
87. Yu, Z.; Cheng, G.; Huang, X.; Li, K.; Cao, X. Neurokinin-1 receptor antagonist SR-140,333: a novel type of drug to treat cerebral ischemia. Neuroreport, 1997, 8, 2117-2119. (Pubitemid 27319656)
88. Castro-Obregón, S.; del Río, G.; Chen, S.F.; Swanson, R.A.; Frankowski, H.; Rao, R.V.; Stoka, V.; Vesce, S.; Nicholls, D.G.; Bredesen, D.E. A ligandreceptor pair that triggers a non-apoptotic form of programmed cell death. Cell Death Differ., 2002, 9, 807-817.
89. Bang, R.; Biburger, M.; Neuhuber, W.L.; Tiegs, G. Neurokinin-1 receptor antagonists protect mice from CD95- and tumor necrosis factor-alphamediated apoptotic liver damage. J. Pharmacol. Exp. Ther., 2004, 308, 1174-1180. (Pubitemid 38263995)
90. Trivedi, M.; Bergasa, N.V. Serum concentrations of substance P in cholestasis. Ann. Hepatol., 2010, 9, 177-180.
91. Ständer, S.; Siepmann, D.; Herrgott, I.; Sunderkötter, C.; Luger, T.A. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One, 2010, 5, e10968.
92. Marriott, I.; Mason, M.J.; Elhofy, A.; Bost, K.L. Substance P activates NFkappaB independent of elevations in intracellular calcium in murine macrophages and dendritic cells. J. Neuroimmunol., 2000, 102, 163-171.
93. Lieb, K.; Fiebich, B.L.; Berger, M.; Bauer, J.; Schulze-Osthoff, K. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J. Immunol., 1997, 159, 4952-4958. (Pubitemid 127471032)
94. Lotz, M.; Vaughan, J.H.; Carson, D.A. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science, 1988, 241, 1218-1221.
95. Laurenzi, M.A.; Persson, M.A.; Dalsgaard, C.J.; Haegerstrand, A. The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide. Scand. J. Immunol., 1990, 31, 529-533. (Pubitemid 20121231)
96. Kincy-Cain, T.; Bost, K.L. Substance P-induced IL-12 production by murine macrophages. J. Immunol., 1997, 158, 2334-2339. (Pubitemid 127470019)
97. Rosenberg, Z.F.; Fauci, A.S. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol. Today, 1990, 11, 176-180. (Pubitemid 20118082)
98. Rosenberg, Z.F.; Fauci, A.S. Immunopathogenesis of HIV infection. FASEB J., 1991, 5, 2382-2390. (Pubitemid 21905785)
99. Pascual, D.W.; Bost, K.L. Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide. Immunology, 1990, 71, 52-56. (Pubitemid 20296071)
100. Castagliuolo, I.; Keates, A.C.; Qiu, B.; Kelly, C.P.; Nikulasson, S.; Leeman, S.E.; Pothoulakis, C. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc. Natl. Acad. Sci. USA, 1997, 94, 4788-4793. (Pubitemid 27194322)
101. Ho, W.Z.; Lai, J.P.; Zhu, X.H.; Uvaydova, M.; Douglas, S.D. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J. Immunol., 1997, 159, 5654-5660. (Pubitemid 127470097)
102. Bost, K.L.; Breeding, S.A.; Pascual, D.W. Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS. Reg. Immunol., 1992, 4, 105-112.
103. Castagliuolo, I.; Riegler, M.; Pasha, A.; Nikulasson, S.; Lu, B.; Gerard, C.; Gerard, N.P.; Pothoulakis, C. Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis. J. Clin. Invest., 1998, 101, 1547-1550. (Pubitemid 28198481)
104. Azzari, C.; Rossi, M.E.; Resti, M.; Caldini, A.L.; Lega, L.; Galli, L.; Fico, E.; Vierucci, A. Changed levels of substance P and somatostatin in HIVpositive children. Pediatr. Med. Chir., 1992, 14, 577-581.
105. Annunziata, P.; Cioni, C.; Toneatto, S.; Paccagnini, E. HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P. AIDS, 1998, 12, 2377-2385. (Pubitemid 28558595)
106. Toneatto, S.; Finco, O.; van der Putten, H.; Abrignani, S.; Annunziata, P. Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS, 1999, 13, 2343-2348.
107. Ho, W.Z.; Cnaan, A.; Li, Y.H.; Zhao, H.; Lee, H.R.; Song, L.; Douglas, S.D. Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. AIDS Res. Hum. Retroviruses, 1996, 12, 195-198. (Pubitemid 26054163)
108. Lai, P.; Ho, W.Z.; Zhan, G.X.; Yi, Y.; Collman, R.G.; Douglas, S.D. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc. Natl. Acad. Sci. USA, 2001, 98, 3970-3975. (Pubitemid 32249882)
109. Patel, L.; Lindley, C. Aprepitant, a novel NK1-receptor antagonist. Expert. Opin. Pharmacother., 2003, 4, 2279-2296.
110. Wang, X.; Douglas, S.D.; Lai, J.P.; Tuluc, F.; Tebas, P.; Ho, W.Z. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J. Neuroimmune Pharmacol., 2007, 2, 42-48.
111. Manak, M.; Moshkoff, D.; Nguyen, L.; Dryga, S.; Lathey, J.; Douglas, S. Anti- HIV activity of aprepitant and synergistic interactions with other antiretrovirals. 15th CROI conference on retrovirus and opportunistic infection, Boston, U.S.A., February 3-6, 2008. http://retroconference.org/2008/Abstracts/ 33182.htm
112. Wang, X.; Douglas, S.D.; Lai, J-P.; Tebas, P.; Lathey, J.L.; Ho, W-Z. Neurokinin- 1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of monocyte-derived macrophages in vitro. 13th CROI conference on retrovirus and opportunistic infection, Denver, U.S.A., February 5-9, 2006. http://www.aegis.com/conferences/croi/2006/511b.pdf
113. King, K.A.; Hu, C.; Rodriguez, M.M.; Romaguera, R.; Jiang, X.; Piedimonte, G. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected eanling rats. Am. J. Respir. Cell Mol. Biol., 2001, 24, 101-107. (Pubitemid 32152070)
114. Robinson, P.; Garza, A.; Moore, J.; Eckols, T.K.; Parti, S.; Balaji, V.; Vallejo, J.; Tweardy, D.J. Substance P is required for the pathogenesis of EMCV infection in mice. Int. J. Clin. Exp. Med., 2009, 2, 76-86.
115. Makhortova, N.R.; Askovich, P.; Patterson, C.E.; Gechman, L.A.; Gerard, N.P.; Rall, G.F. Neurokinin-1 enables measles virus trans-synaptic spread in neurons. Virology, 2007, 362, 235-244. (Pubitemid 46617700)
116. Muñoz, M.; Rosso, M.; Coveñas, R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr. Med. Chem., 2010, 17, 504-516.
117. Muñoz, M.; Rosso, M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest. New Drugs, 2010, 28, 187-193.
118. Palma, C.; Bigioni, M.; Irrissuto, C.; Nardelli, F.; Maggi, C.A.; Manzini, S. Anti- tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br. J. Cancer, 2000, 82, 480-487. (Pubitemid 30045401)
119. Woll, P.J.; Rozengurt E. [D-Arg1-D-Phe5, D-Trp7, 9, Leu11] Substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc. Natl. Acad. Sci. USA, 1988, 35, 1859-1863. (Pubitemid 24315783)
120. Bigioni, M.; Benzo, A.; Irrissuto, C.; Maggi, C.A.; Goso, C. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs, 2005, 16, 1083-1089. (Pubitemid 41565774)
121. Esteban, F.; Muñoz, M.; González-Moles, M.A.; Rosso, M. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metast. Rev., 2006, 25, 137-145. (Pubitemid 43723988)
122. Reeve, J.G.; Bleehen, N.M. [D-Arg1-D-Phe5, D-Trp7, 9, Leu11] Substance P induces apoptosis in lung cancer cell lines in vitro. Biochem. Bioph. Res. Com., 1994, 199, 1313-1319.
123. Rosati, R.; Adil, M.R.; Ali, M.A.; Eliason, J.; Orosz, A.; Sebestye, N.F.; Kalemkerian, G.P. Induction of apoptosis by a short-chain neuropeptide analog in small cell lung cancer-stimulation of multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Peptides, 1998, 19, 1519-1523.
124. Luo, W.; Sharif, T.R.; Sharif, M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res., 1996, 56, 4983-4991. (Pubitemid 26374439)
125. DeFea, K.A.; Vaughn, Z.D.; O'Bryan, E.M.; Nishijima, D.; Dery, O.; Bunnett, N.W: The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proc. Natl. Acad. Sci. USA., 2000, 97, 11086-11091.
126. Akazawa, T.; Kwatra, S.G.; Goldsmith, L.E.; Richardson, M.D.; Cox. E.A.; Sampom, J.H.; Kwatra, M.M. A constiutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J. Neurochem., 2009, 109, 1079-1086.
127. Singh, D.; Joshi, D.D.; Hameed, M.; Qian, J.; Gascon, P.; Maloof, P.B.; Mosenthal, A.; Rameshwar, P. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc. Natl. Acad. Sci. USA., 2000, 97, 388-393. (Pubitemid 30055841)
128. Ziche, M.; Morbidelli, L.; Pacini, M.; Geppetti, P.; Alessandri, G.; Maggi, C.A. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc. Res., 1990, 40, 264-278. (Pubitemid 20327679)
129. Hennig, I.M.; Laissue, J.A.; Horisberger, U.; Reubi, J.C. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int. J. Cancer., 1995, 61, 786-792.
130. Friess, H.; Zhu, Z.; Liard, V.; Shi, X.; Shrikhande, S.V.; Wang, L.; Lieb, K.; Korc, M.; Palma, C.; Zimmermann, A.; Reubi, J.C.; Buchler, M.W. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab. Invest., 2003, 83, 731-742. (Pubitemid 36618051)
131. Guha, S.; Eibl, G.; Kisfalvi, K.; Fan, R.S.; Burdick, M.; Reber, H; Hines, O.J.; Strieter, R.; Rozengurt, E. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,DTrp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res., 2005, 65, 2738-2745. (Pubitemid 40490075)
132. Entschladen, F.; Lang, K.; Drell, T.L.; Joseph, J.; Zaenker, K.S. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol. Immunother., 2002, 51, 467-482.
133. Lang, K.; Drell, T.L.; Lindecke, A.; Niggemann, B.; Kaltschmidt, C.; Zaenker, K.S.; Entschladen, F. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer, 2004, 112, 231-238. (Pubitemid 39244363)
134. Exadaktylos, A.K.; Buggy, D.J.; Moriarty, D.C.; Mascha, E.; Sessler, D.I. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology, 2006, 105, 660-664. (Pubitemid 44477309)
135. Muñoz, M.; Rosso, M.; Casinello, F.; Coveñas, R. Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res. Treat., 2010, 122, 601-603.
136. Muñoz, M.; Rosso, M.; Coveñas, R. The NK-1 receptor: a new target in cancer therapy. Curr. Drug Targets, 2011, 12, (in press).